

**To:** Beck, Nancy[Beck.Nancy@epa.gov]; Pruitt, Scott[Pruitt.Scott@epa.gov]; Brown, Byron[brown.byron@epa.gov]; Jackson, Ryan[jackson.ryan@epa.gov]; Dravis, Samantha[dravis.samantha@epa.gov]  
**Cc:** Gay Ludwick[gay@gdcillc.com]; Roy Bailey[rbailey@gdcillc.com]  
**From:** Roy Bailey  
**Sent:** Sun 7/16/2017 3:36:39 AM  
**Subject:** Attention please  
[EPA Improperly Granted the Wolbachia EUP.DOCX ATT00001.htm](#)

Administrator,

I hope you are well.

I want to bring to your team's immediate attention something that hopefully you and your team will appreciate.

I have included an attachment for your review. The timing is now and hopefully after reviewing the attachment you will consider canceling the field trials until the potential human and environmental impact of the mentioned technology can be reviewed and studied.

There are some very smart and experienced people who understand this technology backwards and forwards and they believe, once reviewed, it won't pass muster. At a minimum, a pause and some time to study it could avoid a disaster and embarrassment to your agency.

I will be more than pleased to put our friends from Intrexon on a call immediately to discuss. After all, they have been in this mosquito business for over 10 years and have extensive knowledge of the subject matter.

Thank you and your team for considering this request and for your attention to the concerns outlined in the memo.

All my best regards and respect

Roy W. Bailey  
CEO  
Giuliani Deason Capital Interests, LLC  
Cell 214.208.1721  
Office 214.378.3663  
[Rbailey@gdcillc.com](mailto:Rbailey@gdcillc.com)  
[Rbailey@baileystrategicadvisors.com](mailto:Rbailey@baileystrategicadvisors.com)

Begin forwarded message:

**From:** "Bobo, Jack" <[JBobo@intrexon.com](mailto:JBobo@intrexon.com)>  
**Date:** July 15, 2017 at 6:59:38 PM PDT

**To:** 'Roy Bailey' <[rbailey@gdcillc.com](mailto:rbailey@gdcillc.com)>  
**Subject:** Memo

---

CONFIDENTIAL TRANSMISSION - To the extent this electronic communication or any of its attachments contain information that is not in the public domain, such information is considered by Intrexon Corporation to be confidential and proprietary. This communication is expected to be read and/or used only by the individual(s) for whom it is intended. If you have received this electronic communication in error, please reply to the sender advising of the error in transmission and delete the original message and any accompanying documents from your system immediately, without copying, reviewing or otherwise using them for any purpose. Thank you for your cooperation.

## **EPA Must Revoke the Improperly Granted *Wolbachia Aedes aegypti* Experimental Use Permit**

EPA's Office of Pesticide Programs improperly granted an Experimental Use Permit (EUP) to MosquitoMate allowing releases of millions of *Wolbachia*-infected *Aedes aegypti* mosquitoes in California and Florida [1]. Oxitec and other commenters submitted substantive comments on the record identifying significant concerns and critical risks associated with the proposed EUP. Notwithstanding these comments, EPA granted the requested EUP to MosquitoMate.

EPA can immediately remedy this improper regulatory approval and all other current *Wolbachia* EUPs. Pursuant to FIFRA Section 5(e) (7 U.S.C. § 136c(e)), the EPA Administrator may revoke an EUP immediately if he finds that its terms or conditions are being violated or that its terms or conditions are inadequate to avoid unreasonable adverse effects on the environment. (See also 40 C.F.R. § 172.10(a)) EPA's regulations provide that a permittee may "contest" the notice of revocation by requesting "an opportunity to confer with the Administrator." The Administrator will issue a final decision within 20 days after such conference. (40 C.F.R. § 172.10(c)) Neither FIFRA nor EPA's regulations provide for a formal hearing to object to revocation of an EUP.

EPA's granting of an experimental use permit to MosquitoMate for an *Aedes aegypti* artificially infected with *Wolbachia pipientis* was premature and did not properly assess the potential adverse impacts to the environment that may result from releases of *Aedes aegypti* artificially infected with a bacterium that is not native to the *Aedes aegypti* microbiome. EPA did not conduct a necessary rigorous assessment of the potential adverse impacts to human health and the environment that could result from uncontained release of *Aedes aegypti* containing this non-native strain of bacteria.

Of particular concern is the fact that horizontal gene transfer could result in *Wolbachia* effectively introducing over one thousand new genes into these modified *Aedes aegypti*. The potential genetic modification to *Aedes aegypti* that may result from use of the wAlbB *Wolbachia* bacterium is wholly undefined. Several studies have shown that horizontal gene transfer between *Wolbachia* and their insect hosts may result in gene transfers ranging from nearly the entire *Wolbachia* genome (>1 megabase) to short insertions (<500 base pairs) into various hosts [2-5]. Effectively the *Wolbachia* IIT approach could introduce over one thousand new genes into *Aedes aegypti* with unknown consequences, and if they provide a positive selection to the mosquito in the environment this could result in novel strains pervading and spreading through the population.

Critical questions about the *Wolbachia Aedes aegypti* that EPA did not answer prior to granting the EUP include the following:

- Can the *Wolbachia* mosquito escape the confined conditions in which it is reared?
- What is the likelihood that the *Wolbachia* mosquitoes will survive, reproduce, and disperse once released into the environment? Modelling has shown that conditions of lower competition can favor the spread of *Wolbachia*-infected females [6-8]. In other words, as a mosquito population is reduced, or if a population is already low, the chances of *Wolbachia* invading the wild population are increased.

- What are the potential impacts of the *Wolbachia* mosquitoes in the environment, including on humans? The whole genome of *Wolbachia* can transfer to a host genome, meaning a host mosquito could be transformed with over one thousand new genes with unpredictable results [2-5]. Horizontal gene transfer (HGT) can transfer genes between *Wolbachia* and its host in *Aedes aegypti* [12] and several other mosquito species [13, 25]. Therefore, *Wolbachia* can genetically transform its host with functional genes with currently unknown consequences. EPA did not require any investigation or risk assessment of these potential consequences.

Moreover, widespread recombination occurs throughout the *Wolbachia* genome [14], increasing the likelihood of genes changing as the *Wolbachia* evolves. Moreover, temperature impacts *Wolbachia*-malaria interaction in mosquitoes suggesting impact of transfection might vary across diverse environments [17]. Also, it has been shown that *Wolbachia* enhances West Nile virus infection in the mosquito *Culex tarsalis*. This introduces the possibility that the *Wolbachia* infection could spread to *Culex* populations in areas where West Nile virus is a concern [18]. Similarly, *Wolbachia* can enhance malaria parasite infection in two genera of mosquitoes [19-21].

- What are the likely consequences for the surrounding environment, should the *Wolbachia* mosquitoes survive and establish in the environment? There is evidence that male age and overcrowding during development (*i.e.*, under mass rearing conditions required to produce enough males for IIT to be effective) can reduce the cytoplasmic incompatibility effect in certain insects, rendering the males fertile [26] and able to spread the *Wolbachia* infection through surviving females. EPA should have required a study to assess whether this effect is likely to be seen in *Aedes aegypti*. EPA should have required additional analysis to assess interactions of *Aedes aegypti*, potential pathogens, and *Wolbachia*, to ensure that *Wolbachia* does not ultimately select for more dangerous pathogens in *Aedes aegypti* [22].

EPA should have, but did not, evaluate these and other critical risk assessment questions before it granted the *Wolbachia* EUP extension, which allows the release of 14 million of these inadequately evaluated *Wolbachia*-infected *Aedes aegypti* into the environment. As is demonstrated in the published literature referenced below, and as Oxitec and other commenters demonstrated on the record, releases of such massive numbers of these artificially infected *Aedes aegypti* could result in serious unreasonable adverse effects to the environment.

## References

- 1) USEPA, Amendments, Extensions, and/or Issuances of Experimental Use Permits, 81 Federal Register 69059 October 5, 2016.
- 2) Dunning Hotopp, J.C., *et al.*, Widespread lateral gene transfer from intracellular bacteria to multicellular eukaryotes. *Science*, 2007. 317: p. 1753-6.
- 3) Fenn, K., *et al.* Phylogenetic relationships of the *Wolbachia* of nematodes and arthropods. *PLoS Pathog*, 2006. 2: p. e94.
- 4) Hou, Q., *et al.*, A case of horizontal gene transfer from *Wolbachia* to *Aedes albopictus* C6/36 cell line. *Mob Genet Elements*, 2014. 4: p. e28914.
- 5) Kondo, N., *et al.* Genome fragment of *Wolbachia* endosymbiont transferred to X chromosome of host insect. *Proc Natl Acad Sci U S A*, 2002. 99: p. 14280-5.
- 6) Endersby, N.M. and A.A. Hoffmann, Effect of *Wolbachia* on insecticide susceptibility in lines of *Aedes aegypti*. *Bulletin Entomol Res*, 2013. 103(3): p. 269-77.
- 7) Hancock, P.A., S.P. Sinkins, and H.C.J. Godfray, Population dynamic models of the spread of *Wolbachia*. *The American Naturalist*, 2011. 177(3): p. 323-333.
- 8) Jansen, V.A.A., M. Turelli, and H.C.J. Godfray, Stochastic spread of *Wolbachia*. *Proceedings of the Royal Society B: Biological Sciences*, 2008. 275(1652): p. 2769-2776.
- 9) O'Connor, L., *et al.*, Open release of male mosquitoes infected with a *Wolbachia* biopesticide: field performance and infection containment. *PLoS Negl Trop Dis*, 2012. 6(11): p. e1797.
- 10) Alphey, L., Natural and engineered mosquito immunity. *Journal of Biology*, 2009. 8: p. 40.
- 11) Ye, Y.H., *et al.*, *Wolbachia* reduces the transmission potential of dengue-infected *Aedes aegypti*. *PLoS Negl Trop Dis*, 2015. 9: e0003894.
- 12) Klasson, L., *et al.*, Horizontal gene transfer between *Wolbachia* and the mosquito *Aedes aegypti*. *BMC Genomics*, 2009. 10(1): p. 33.
- 13) Woolfit, M., *et al.*, An ancient horizontal gene transfer between mosquito and the endosymbiotic bacterium *Wolbachia pipientis*. *Molecular biology and evolution*, 2009. 26(2): p. 367-74.
- 14) Baldo, L., *et al.*, Widespread recombination throughout *Wolbachia* genomes. *Mol Biol Evol*, 2006. 23(2): p. 437-49.
- 15) Carrington, L.B., A.A. Hoffmann, and A.R. Weeks, Monitoring long-term evolutionary changes following *Wolbachia* introduction into a novel host: the *Wolbachia* popcorn infection in

*Drosophila simulans*. *Proc Biol Sci*, 2010. 277(1690): p. 2059-68.

16) Hughes, G.L., *et al.*, Native microbiome impedes vertical transmission of *Wolbachia* in *Anopheles* mosquitoes. *Proc Natl Acad Sci U S A*, 2014. 111: p. 12498-503.

17) Murdock, C.C., *et al.*, Temperature alters *Plasmodium* blocking by *Wolbachia*. *Sci Rep*, 2014. 4: p. 3932.

18) Dodson, B.L., *et al.*, *Wolbachia* enhances West Nile Virus (WNV) infection in the mosquito *Culex tarsalis*. *PLoS Negl Trop Dis*, 2014. 8(7): p. e2965.

19) Hughes, G.L., *et al.* *Wolbachia* can enhance *Plasmodium* infection in mosquitoes: implications for malaria control? *PLoS Pathog*, 2014. 10: p. e1004182.

20) Hughes, G.L., *et al.* *Wolbachia* strain wAlbB enhances infection by the rodent malaria parasite *Plasmodium berghei* in *Anopheles gambiae* mosquitoes. *Appl Environ Microbiol*, 2012. 78: p. 1491-5.

21) Zele, F. *et al.*, *Wolbachia* increases susceptibility to *Plasmodium* infection in a natural system. *Proc Biol Sci*, 2014. 281: p. 20132837.

22) Brelsfoard, C.L. and S.L. Dobson, *Wolbachia*-based strategies to control insect pests and disease vectors. *AsPac J Mol Biol Biotechnol*, 2009. 17(3): p. 55-63.

23) Werren, J.H., L. Baldo, and M.E. Clark, *Wolbachia*: master manipulators of invertebrate biology. *Nat Rev Microbiol*, 2008. 6(10): p. 741-51.

24) Marshall, J.L., Rapid evolution of spermathecal duct length in the *Allonemobius socius* complex of crickets: species, population and *Wolbachia* effects. *PLoS One*, 2007. 2(8): p. e720.

25) Baldo, L., *et al.*, Insight into the routes of *Wolbachia* invasion: high levels of horizontal transfer in the spider genus *Agelenopsis* revealed by *Wolbachia* strain and mitochondrial DNA diversity. *Mol Ecol*, 2008. 17(2): p. 557-69.

26) Yamada, R., *et al.*, Male development time influences the strength of *Wolbachia*-induced cytoplasmic incompatibility expression in *Drosophila melanogaster*. *Genetics*, 2007. 177(2): p. 801-8.